Sanofi and Regeneron Announce Approval of Praluent(®) (alirocumab) for the
Treatment of Hypercholesterolemia in the European Union
- Praluent will be available in both a 75 mg and 150 mg dose for self-
administration every two weeks -
Paris and ...
↧